Can anti-osteoporotic therapy reduce adjacent fracture in magnetic resonance imaging-proven acute osteoporotic vertebral fractures? by Ying-Chou Chen & Wei-Che Lin
RESEARCH ARTICLE Open Access
Can anti-osteoporotic therapy reduce
adjacent fracture in magnetic resonance
imaging-proven acute osteoporotic
vertebral fractures?
Ying-Chou Chen1* and Wei-Che Lin2
Abstract
Background: Adjacent fracture of the cemented vertebrae result from crushed fragile trabeculae during follow-up,
suggesting impaired bone marrow integrity. This study aimed to determine if anti-osteoporotic therapy can
decrease the risk of adjacent fracture in patients after vertebroplasty.
Methods: This retrospective study reviewed of cases of osteoporotic patients with magnetic resonance imaging
(MRI)-proven acute vertebral fractures between 2001 and 2007. Osteoporotic patients were investigated as
determined by pre-operative MRI with subsequent adjacent fracture of the cemented vertebrae and for the
possibility of anti-osteoporotic therapy decreasing the progression of collapse after a minimum of 6 months follow-up.
All associated co-morbidities were recorded, as well as the use of anti-osteoporotic drugs (i.e., bisphosphonate,
raloxifen, calcitonin, and teriparatide). Cox regression analysis was also performed.
Results: The 192 vertebral fractured patients who underwent vertebroplasty and anti-osteoporotic therapy
had a mean age of 74.40 ± 6.41. The basic characteristics of patients with and without adjacent fracture
differed in age, body mass index, rheumatoid arthritis, and use of glucocorticoids and anti-osteoporotic
drugs (Table 1). Using the Kaplan-Meier curve, anti-osteoporotic therapy after vertebroplasty had a
significant effect on adjacent fracture (p = 0.037, by log rank text). After adjusting for potential confounders,
patients with anti-osteoporotic therapy still had a lower adjacent fracture rate than patients without anti-
osteoporotic therapy (p = 0.006; HR: 2.137, 95 % CI: 1.1238–3.690). The adjacent fracture rate also increased
in old age (p = 0.019; HR: 1.049; 95 % CI:1.008–1.039) and among smokers (p = 0.026; HR: 3.891; 95 % CI:
1.175–12.890).
Conclusions: In this study, adjacent fracture of cemented vertebrae is inevitable after vertebroplasty but
can be mitigated by anti-osteoporotic therapy to increase bone mass.
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Background
Spine fractures are common with aging. The risk of
osteoporotic spine compression fracture is estimated to
be 18 % in women and 11 % in men [1]. Symptomatic
spine fractures increase mortality by up to 15 % [2] and
some become disabled by severe pain and lasts for 2–3
months.
Acute vertebral fractures with persistent pain are fre-
quently managed with vertebroplasty [3]. It had been
widely used in recent decade. Although it had favorable
clinical outcomes, few studies on mortality among pa-
tients with vertebroplasty were reported [4, 5]. Despite
its safe and efficient, there are still some risks, includ-
ing the development of new adjacent fractures at the
non-treated vertebrae [6].
Anti-osteoporotic therapy is reported to increase
bone mineral density. Patients who received anti-
osteoporotic treatment reduced incidences of vertebral
fractures [7]. If treating osteoporosis have benefit on
adjacent fracture after vertebroplasty, it will had im-
portant implications in skeletal health care. So this
study investigate whether osteoporosis treatment can
affect adjacent fracture rates in patients after vertebro-
plasty procedure.
Methods
The retrospective study reviewed osteoporosis patients
with acute vertebral fractures which were proven by
magnetic resonance imaging (MRI) and defined as
low signal intensity (SI) on T1 and enhanced SI at
T2-weighted of the injured vertebral body [8]. All of
the patients were treated with vertebroplasty were
performed in all of the patients. Chang Gang Memor-
ial Hospital’s institutional review board reviewed and
approved the study protocol, which was conducted in
Good Clinical Practice Guidelines. In accordance with
local government's law, no additional informed con-
sent was required. All information was de-identified
before data analysis.
Only those treated with for a single vertebral fracture
were enrolled. Patients previously using anti-osteoporotic
drugs were also been excluded. The medical records were
reviewed and the new fractures were evaluated from the
imaging follow-up.
Pre- and post-vertebroplasty radiographs and those taken
more than 6 months after the procedure were obtained.
Those without available radiographs were excluded from
the study.
Standard methods was used to measure the height of
the anterior border of the collapsed vertebral body [9].
The anterior vertebral height (AVH) was measured
Differences of AVH within 1 mm were considered un-
changed [10] and to avoid biases from technical factors
or inappropriate measurement.
All of the study patients were recorded with, age, sex,
body mass index (BMI, kg/m2), and all co-morbidities
such as diabetes, hypertension, and liver and renal disease.
The use of anti-osteoporotic drugs (i.e., alendronate,
raloxifen, calcitonin, and teriparatide) were reviewed. The
duration of osteoporotic therapy was followed by local
government's policy with teriparatide (18 months),
bisophosphonate and raloxifen, calcitonin (long term
used).
Statistical analysis
Statistical analysis was performed using the SPSS soft-
ware, version 21.0 (SPSS, Chicago, IL, USA). Patient
characteristics were reported as simple descriptive
statistics (i.e., mean ± standard deviation [SD]). Differ-
ent groups of anti-osteoporotic agents were compared
using Kaplan-Meyer analysis with the log rank test. Inde-
pendent t-test was compared for independent means,
while relationships between categorical variables were
evaluated by the Chi-square test. Cox regression test was
used for potential confounders.
Results
Of 192 patients enrolled in this study, 86 (44.8 %) used
alendroante, 38 (19.8 %) used raloxifen, 18 (9.4 %) used
calcitonin, and 12 (6.3 %) used teriparatide. All were grade
3 by semi-quantitative grading for vertebral fracture and
had a T score less than −2.5 by bone densitometry. Their
mean age was 74.40 ± 6.41 years. 84 patients had adjacent
fracture (Fig 1). The basic characteristic of patients with
and without adjacent fracture differed in age, BMI,
rheumatoid arthritis, and glucocorticoid and anti-
osteoporotic therapy use (Table 1).
By the Kaplan-Meier curve analysis, anti-osteoporotic
treatment after vertebroplasty had a significant benefit
on adjacent fracture (p = 0.037, by log rank test) (Fig. 2).
After adjusting for confounding factors such as smok-
ing, alcohol consumption, hypertension, diabetes,
cardiovascular, pulmonary, and liver diseases, and
glucocorticoid use, those with anti-osteoporotic treat-
ment still had a lower adjacent fracture rate than those
who did not receive anti-osteoporotic therapy (p =
0.006; HR: 2.137; 95 % CI: 1.1238–3.690). The adjacent
fracture rate also increased in old age (p = 0.019; HR:
1.049; 95 % CI: 1.008–1.039) and among smokers (p =
0.026; HR: 3.891; 95 % CI:1.175–12.890) (Table 2).
Evaluating the relationship between anti-osteoporotic
druguse and adjacent fracture, the use of alendronatewas
associated with a significant reduction in adjacent
fracture (p = 0.011), while raloxifen, calcitoninc, and
teriparatide did not decrease adjacent fracture rate
(Table 3).
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Discussion
Osteoporotic compression fractures increase the risk
of new vertebral compression fracture even without
percutaneous vertebroplasty [11]. Since vertebral com-
pression fracture can lead to a collapse of adjacent
vertebral bodies, it usually provokes a cascade of sub-
sequent fractures.
Fracture of the adjacent vertebrae is a unique com-
plication associated with vertebroplasty. The effects of
vertebroplasty will increase strength of the stabilized
vertebral bodies be greatest at vertebral levels near
the treated vertebral body and augmented spinal
segment have shown increased nucleus pulposus pres-
sure, and lead to deformation of the adjacent endplate
[12, 13], followed by decreasing segmental strength
[14, 15]. Some studies report that adjacent vertebral
fracture occurs sooner than non-adjacent fractures
[16], and majority of cases occurring within 30 days
of surgery [17]. On the other hand, other studies re-
fute these findings and find that adjacent untreated
vertebral bodies do not undergo immediate changes
after vertebroplasty and that intervention did not re-
sult in adjacent vertebral fractures [18, 19].
Adjacent vertebral fractures can be prevented by cor-
rectly recognizing and performing kyphoplasty in all
fractured vertebrae identified by pre-operative MRI. Fur-
thermore, the reported inevitable side effects of long-
term analgesic medication in patients with chronic pain
can be avoided [20, 21] through anesthesia and more
radiation.
Anti-osteoporosis includes selective estrogen recep-
tor modulators, bisphosphonates, and parathyroid
hormone analogs. Among them, bisphosphonates are
the compounds most commonly used drugs, which
increase bone mass in osteoporotic patients [3, 8, 15].
In a study, alendronate group had less mean loss of
vertebral height after 3 years of treatment than the
placebo group [15].
In this study, anti-osteoporotic therapy significantly
reduces adjacent fracture. Alendronate is the main drug
Fig. 1 A comparison of adjacent fracture for those with (blue line) and without (green line) anti-osteoporotic therapy, by Kaplan-Meier analysis








Age (years) 75.83 ± 6.28 73.28 ± 6.31 0.006
Body mass index
(kg/m2)
21.68 ± 4.11 24.36 ± 4.63 0.001
Sex (% Female) 68 (81.0 %) 98 (90.7 %) 0.057
Spine fracture
(number)
1.18 ± 1.33 1.89 ± 1.87 0.965
Smoking 8 (9.5) 2 (1.9) 0.023
Alcohol
consumption
0 (0) 2 (1.9) 0.505
Rheumatoid arthritis 10 (11.9) 2 (1.9) 0.006
Diabetes mellitus (%) 18 (21.4) 28 (25.9) 0.5
Hypertension 44 (52.4) 48 (44.4) 0.309
Diseases
Cardiovascular 0 (0) 2 (1.9) 0.505
Pulmonary 6 (7.1) 2 (1.9) 0.141
Liver 2 (2.4) 6 (5.6) 0.469
Glucorcorticoid use 18 (21.4) 10 (9.3) 0.023
Anti-osteoporotic
drugs use
58 (69) 89 (82.4) 0.031
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identified to improve adjacent fracture. Smoking and
old age increases adjacent fracture so such patients
warrant aggressive treatment.
This study has several limitations. First, the sample
size is small. futhermore, because of the retrospective
design, this study did not include datas, such as the
use of calcium and vitamin D supplements. Nonethe-
less, in this cohort, as much data as possible was
collected. Besides this study also included only fra-
gility fractures in patients older than 50 years and
exclude a secondary etiology such as cancer or pyo-
genic infection by MRI scans. Thus, the patients’
fractures were due to osteoporosis.
Conclusions
Vertebroplasty can stabilize an fractured vertebra, but
collapse of the cemented vertebrae can occur rapidly.
In this study, we found adjacent fracture of a cemented
vertebra is inevitable after vertebroplasty. Increase bone
mass by anti-osteoporotic therapy after vertebroplasty
may prevent the further collapse of the cemented
vertebra.
Fig. 2 Vertebroplasty was performed for 10th thoracic vertebra (a, b). c Patient developed a new adjacent compression fracture of 11th thoracic
vertebra 16 months later






Table 2 Multivariable Cox regression analysis of the hazard





HR (95 % CI)




−0.055 0.036 2.344 0.126 0.946
(0.882–1.016)
Sex −0.595 0.515 1.335 0.248 0.551
(0.201–1.513)




−13.295 383.923 0.001 0.972 0.00 (0.000)
Rheumatoid
arthritis




0.262 0.300 0.762 0.383 1.298
(0.722–2.337)
Hypertension −0.334 0.255 1.709 0.191 0.716
(0.434–1.181)
Diseases
Cardiovascular −12.071 442.926 0.001 0.978 0.000 (0.000)
Pulmonary −0.159 0.552 0.082 0.774 0.853
(0.289–2.519)









0.759 0.279 7.426 0.006 2.137
(1.238–3.690)
Abbreviations: HR hazard ratio; SE standard error
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